ATXI
AVENUE THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.48
−15.30%Price chart
Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14Sep 17
Key dataSep 17, 2026
Open$0.55
From 52W high−48.42%
Volume10715.00
Market cap$1.52M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 17, 2026
Open
$0.55
From 52W high
−48.42%
Volume
10715.00
Market cap
$1.52M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
49.1
MomentumView details →
1D Return
−15.30%
YTD Return
−29.79%
SummaryUpdated Jun 1, 2026
Avenue Therapeutics, Inc. (NASDAQ:ATXI) is a specialty pharmaceutical company founded in 2015 and headquartered in New York, New York. The company went public in June 2017 and focuses on developing and commercializing pharmaceutical products specifically designed for use in acute and intensive care hospital settings. Avenue Therapeutics operates as a clinical-stage biotechnology company with its primary asset being an intravenous formulation of Tramadol currently in Phase III clinical trials.
Similar companies
Latest newsMore news →
No recent news for ATXI.